Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aligos Therapeutics, Inc.

11.67
+0.23002.01%
Volume:97.96K
Turnover:1.15M
Market Cap:71.35M
PE:-0.91
High:12.12
Open:11.49
Low:11.39
Close:11.44
Loading ...

Company Profile

Company Name:
Aligos Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
68
Office Location:
One Corporate Drive,2nd Floor,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Directors

Name
Position
Lawrence M. Blatt
Chief Executive Officer and Director
Jack B. Nielsen
Chair and Director
Leonid Beigelman
President and Director
Carole Nuechterlein
Director
K. Peter Hirth
Director
Kathleen Sereda Glaub
Director
Peter Moldt
Director
Thomas Woiwode
Director

Shareholders

Name
Position
Lawrence M. Blatt
Chief Executive Officer and Director
Lesley Ann Calhoun
Executive Vice President, Chief Financial Officer
Julian A. Symons
Executive Vice President, Chief Scientific Officer
Leonid Beigelman
President and Director
Lucinda Y. Quan
Executive Vice President, Chief Business Officer and General Counsel